SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-007636
Filing Date
2023-03-13
Accepted
2023-03-13 08:23:06
Documents
14
Period of Report
2023-03-13
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20230313.htm   iXBRL 8-K 39856
2 EX-99.1 ovid2022exhibit991.htm EX-99.1 76191
6 img34400995_0a.jpg GRAPHIC 17099
  Complete submission text file 0001628280-23-007636.txt   291951

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20230313.xsd EX-101.SCH 1896
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20230313_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20230313_pre.xml EX-101.PRE 13042
8 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20230313_htm.xml XML 12419
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 23725804
SIC: 2834 Pharmaceutical Preparations